Cargando…
Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
BACKGROUND/AIM: Cardiotoxicity is a potential complication of anticancer therapy. While guidelines have been developed to assist practitioners, an effective, evidence based clinical pathway for the treatment of cardiotoxicity has not yet been developed. The aim of this study was to describe the jour...
Autores principales: | Clark, Robyn A., Marin, Tania S., McCarthy, Alexandra L., Bradley, Julie, Grover, Suchi, Peters, Robyn, Karapetis, Christos S., Atherton, John J., Koczwara, Bogda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048085/ https://www.ncbi.nlm.nih.gov/pubmed/32154020 http://dx.doi.org/10.1186/s40959-019-0046-5 |
Ejemplares similares
-
Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment
por: Clark, Robyn A., et al.
Publicado: (2017) -
The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review
por: Conway, Aaron, et al.
Publicado: (2015) -
Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure‐related causes after cancer therapy
por: Versace, Vincent L., et al.
Publicado: (2016) -
Serial monitoring of LV function following chemotherapy: assessment using advanced echocardiography and cardiovascular magnetic resonance
por: Grover, Suchi, et al.
Publicado: (2014) -
Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer
por: Abbas, M. Nazim, et al.
Publicado: (2021)